After Daniel Vasella.......will Novartis maintain its Charm???

I have read a lot about Daniel Vasella, how he changed the fortune of Novartis,.......In Basel two companies campuses are looked for, one is Roche and another is Novartis.......Both with different work style and generally people tell me that none of the companies recruit other's employees......I am unable to confirm it.....but working in Novartis Basel office is a different ball game.......

Daniel Vasella was the man who made a difference for the company and some analyst reports have predicted that Novartis will be heading for number 1 position in terms of Pharma revenues by year 2018......the recent news of Daniel Vasella quitting as CEO was shocking for me......according to report investors were happy with the decision but we have to see how the market is going to behave further....what will be companies new M&A and R&D policies......time will say if Novartis will maintain its charm? 

Parexel!

Parexel just went into buying out and expending its portfolio in Regulatory approval processes. Though Quintile always had the first mover advantage and icon the smallest baby in the industry has matured quite fast. What i have observed is that PPD and Parexel have slight conservative approach compared to Quintiles and Icon in terms of their portfolio expansion and establishment in new territories. Like Quintiles new move in Biosimilars and RA therapy as such. Parexel went on to penetrate in the field of Biosimilars but more to watch from this CRO in terms of its strategic expansion in APAC, Middle east and Latin America

Whistleblower!

After the provisions in the whistle blower act, pharma has seen many illegal marketing tactics coming out in public, Pfizer has been targeted many a times and it’s still with its competitor Novartis considered the best in the field of Pharma Marketing

We now need to watch how Pfizer is promoting Tofacitinib and Eliquis?

Last month what astonished me that Amgen was ready to pay back around 750 M USD to federal government as it already knew that it had to pay the price for use of illegal marketing tactics for Arnasep. This is not the first case, for the past 20 years we have seen a tremendous increase in these types of marketing tactics by Pharma and biopharma companies to allure physicians and primary health bodies. As Amgen had already kept aside 750 M USD from its revenue. Going forward we will observe that companies as part of their marketing budget will keep additional 1B USD in cash for these type of situations.

As whistleblower act has been promoted in US we have more to watch!